 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
11 News |  |
- |||| LAE005 / Laekna Therap, spartalizumab (PDR001) / Novartis
Trial termination: A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (clinicaltrials.gov) - Jan 13, 2025
P1, N=154, Terminated, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Terminated; The early termination was based on a business decision that FAZ053 would no longer be formulated and was not a consequence of any safety concern.
- LAE005 / Laekna Therap, afuresertib (LAE002) / Laekna Therap
Phase I/II clinical trials of LAE005, afuresertib plus nab-paclitaxel in patients with advanced solid tumors, primarily in patients with triple-negative breast cancer (TNBC) (Section 49) - Mar 5, 2024 - Abstract #AACR2024AACR_5196;
Active, not recruiting --> Terminated; The early termination was based on a business decision that FAZ053 would no longer be formulated and was not a consequence of any safety concern. Abstract is embargoed at this time.
- || LAE005 / Laekna Therap, spartalizumab (PDR001) / Novartis
Trial completion date, Trial primary completion date: A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (clinicaltrials.gov) - Feb 15, 2024
P1, N=154, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Abstract is embargoed at this time. Trial completion date: Jun 2024 --> Nov 2024 | Trial primary completion date: Jun 2024 --> Nov 2024
- || LAE005 / Laekna Therap, afuresertib (LAE002) / Laekna Therap
Trial completion, Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Metastases: PhI to Solid Tumors and PhII to Locally Advanced or mTNBC (clinicaltrials.gov) - Jan 31, 2024
P1, N=21, Completed, Sponsor: Laekna Limited
Trial completion date: Jun 2024 --> Nov 2024 | Trial primary completion date: Jun 2024 --> Nov 2024 Recruiting --> Completed | Phase classification: P1/2 --> P1 | N=101 --> 21 | Trial completion date: Jul 2024 --> Dec 2023 | Trial primary completion date: Mar 2024 --> Dec 2023
- || LAE005 / Laekna Therap, spartalizumab (PDR001) / Novartis
Trial completion date, Trial primary completion date: A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (clinicaltrials.gov) - Jul 29, 2022
P1, N=154, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | Phase classification: P1/2 --> P1 | N=101 --> 21 | Trial completion date: Jul 2024 --> Dec 2023 | Trial primary completion date: Mar 2024 --> Dec 2023 Trial completion date: Mar 2023 --> Jun 2024 | Trial primary completion date: Mar 2023 --> Jun 2024
- || LAE005 / Laekna Therap, spartalizumab (PDR001) / Novartis
Trial completion date, Trial primary completion date: A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (clinicaltrials.gov) - May 19, 2022
P1, N=154, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Mar 2023 --> Jun 2024 | Trial primary completion date: Mar 2023 --> Jun 2024 Trial completion date: Jul 2022 --> Mar 2023 | Trial primary completion date: Apr 2022 --> Mar 2023
- | LAE005 / Laekna Therap, spartalizumab (PDR001) / Novartis
Trial completion date: A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (clinicaltrials.gov) - Jan 11, 2022
P1, N=154, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jul 2022 --> Mar 2023 | Trial primary completion date: Apr 2022 --> Mar 2023 Trial completion date: Apr 2022 --> Jul 2022
- Opdivo (nivolumab) / Ono Pharma, BMS
IMMUNE CHECKPOINT INHIBITORS PROVIDE FAVORABLE RESPONSES IN PATIENTS WITH RECURRENT CHORDOMA ([VIRTUAL]) - Nov 26, 2021 - Abstract #CTOS2021CTOS_36;
Nearly all patients had some clinical benefit to ICI with limited toxicities, and responses were relatively durable, though longer among patients achieving a CR/PR compared to SD. These promising data provide support for the prospective evaluation of ICI in patients with Chordoma.
- || LAE005 / Laekna Therap, spartalizumab (PDR001) / Novartis
Trial primary completion date: A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (clinicaltrials.gov) - Apr 28, 2021
P1, N=154, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
These promising data provide support for the prospective evaluation of ICI in patients with Chordoma. Trial primary completion date: Jun 2021 --> Apr 2022
- | LAE005 / Laekna Therap, spartalizumab (PDR001) / Novartis
Trial completion date: A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (clinicaltrials.gov) - Feb 24, 2021
P1, N=154, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2021 --> Apr 2022 Trial completion date: Jun 2021 --> Apr 2022
- || LAE005 / Laekna Therap, spartalizumab (PDR001) / Novartis
Trial completion date, Trial primary completion date: A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (clinicaltrials.gov) - Jun 22, 2020
P1, N=154, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jun 2021 --> Apr 2022 Trial completion date: Nov 2020 --> Jun 2021 | Trial primary completion date: Nov 2020 --> Jun 2021
- || LAE005 / Laekna Therap, spartalizumab (PDR001) / Novartis
Trial completion date, Trial primary completion date: A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (clinicaltrials.gov) - Jan 21, 2020
P1, N=154, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Nov 2020 --> Jun 2021 | Trial primary completion date: Nov 2020 --> Jun 2021 Trial completion date: Feb 2020 --> Nov 2020 | Trial primary completion date: Feb 2020 --> Nov 2020
- || LAE005 / Laekna Therap, spartalizumab (PDR001) / Novartis
Enrollment closed, Trial completion date, Trial primary completion date: A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (clinicaltrials.gov) - Mar 25, 2019
P1, N=154, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Feb 2020 --> Nov 2020 | Trial primary completion date: Feb 2020 --> Nov 2020 Recruiting --> Active, not recruiting | Trial completion date: Nov 2019 --> Feb 2020 | Trial primary completion date: Nov 2019 --> Feb 2020
- || LAE005 / Laekna Therap, spartalizumab (PDR001) / Novartis
Trial completion date, Trial primary completion date: A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (clinicaltrials.gov) - Jan 22, 2019
P1, N=155, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial completion date: Nov 2019 --> Feb 2020 | Trial primary completion date: Nov 2019 --> Feb 2020 Trial completion date: Feb 2020 --> Nov 2019 | Trial primary completion date: Feb 2020 --> Nov 2019
- || LAE005 / Laekna Therap, spartalizumab (PDR001) / Novartis
Enrollment change, Trial completion date, Trial primary completion date: A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (clinicaltrials.gov) - Jun 19, 2018
P1, N=212, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Feb 2020 --> Nov 2019 | Trial primary completion date: Feb 2020 --> Nov 2019 N=315 --> 212 | Trial completion date: Oct 2019 --> Feb 2020 | Trial primary completion date: Oct 2019 --> Feb 2020
- ||| LAE005 / Laekna Therap, spartalizumab (PDR001) / Novartis
New P1 trial: A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (clinicaltrials.gov) - Dec 19, 2017
P1, N=315, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||| LAE005 / Laekna Therap, spartalizumab (PDR001) / Novartis
Enrollment open: A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (clinicaltrials.gov) - Feb 6, 2017
P1, N=315, Recruiting, Sponsor: Novartis Pharmaceuticals
N=315 --> 212 | Trial completion date: Oct 2019 --> Feb 2020 | Trial primary completion date: Oct 2019 --> Feb 2020 Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2019 --> Oct 2019 | Not yet recruiting --> Recruiting